These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1514881)

  • 1. Zacopride in schizophrenia: a single-blind serotonin type 3 antagonist trial.
    Newcomer JW; Faustman WO; Zipursky RB; Csernansky JG
    Arch Gen Psychiatry; 1992 Sep; 49(9):751-2. PubMed ID: 1514881
    [No Abstract]   [Full Text] [Related]  

  • 2. LAS 30451: a novel 5-HT3 antagonist.
    Martin M; Rosell R; Guillem V; Díaz-Rubio E; Moreno I; Soriano V; Fernández A; Pérez A
    Eur J Cancer; 1993; 29A Suppl 1():S33-4. PubMed ID: 8427723
    [No Abstract]   [Full Text] [Related]  

  • 3. Cisplatin-induced conditioned taste aversion: attenuation by dexamethasone but not zacopride or GR38032F.
    Mele PC; McDonough JR; McLean DB; O'Halloran KP
    Eur J Pharmacol; 1992 Aug; 218(2-3):229-36. PubMed ID: 1330594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-HT3 receptor antagonists reverse helpless behaviour in rats.
    Martin P; Gozlan H; Puech AJ
    Eur J Pharmacol; 1992 Feb; 212(1):73-8. PubMed ID: 1532555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonergic mechanisms and current and future psychiatric practice.
    Dubovsky SL; Thomas M
    J Clin Psychiatry; 1995; 56 Suppl 2():38-48. PubMed ID: 7844106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zacopride, a potent 5-HT3 antagonist.
    Smith WW; Sancilio LF; Owera-Atepo JB; Naylor RJ; Lambert L
    J Pharm Pharmacol; 1988 Apr; 40(4):301-2. PubMed ID: 2900319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of 5-HT3 recognition sites in human brain tissue using [3H]zacopride.
    Barnes NM; Costall B; Ironside JW; Naylor RJ
    J Pharm Pharmacol; 1988 Sep; 40(9):668. PubMed ID: 2907045
    [No Abstract]   [Full Text] [Related]  

  • 8. Emetic activity of zacopride in ferrets and its antagonism by pharmacological agents.
    Sancilio LF; Pinkus LM; Jackson CB; Munson HR
    Eur J Pharmacol; 1990 Jun; 181(3):303-6. PubMed ID: 2384137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [3H]zacopride: ligand for the identification of 5-HT3 recognition sites.
    Barnes NM; Costall B; Naylor RJ
    J Pharm Pharmacol; 1988 Aug; 40(8):548-51. PubMed ID: 2907008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potent 5-HT3 receptor antagonist (R)-zacopride labels an additional high affinity site in the central nervous system.
    Kidd E; Bouchelet de Vendegies I; Levy JC; Hamon M; Gozlan H
    Eur J Pharmacol; 1992 Jan; 211(1):133-6. PubMed ID: 1618262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zacopride and its optical isomers produce stereoselective antagonism of a 2-methylserotonin discriminative stimulus.
    Young R; Glennon RA
    Eur J Pharmacol; 1992 Feb; 212(1):117-9. PubMed ID: 1555633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-HT3 receptor agonism may be responsible for the emetic effects of zacopride in the ferret.
    Middlefell VC; Price TL
    Br J Pharmacol; 1991 May; 103(1):1011-2. PubMed ID: 1831684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the 5-HT3 receptor antagonist properties of ICS 205-930, GR38032F and zacopride.
    Cohen ML; Bloomquist W; Gidda JS; Lacefield W
    J Pharmacol Exp Ther; 1989 Jan; 248(1):197-201. PubMed ID: 2521513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of renzapride, a novel prokinetic agent, in diabetic gastroparesis.
    Mackie AD; Ferrington C; Cowan S; Merrick MV; Baird JD; Palmer KR
    Aliment Pharmacol Ther; 1991 Apr; 5(2):135-42. PubMed ID: 1888816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of stereoisomers of zacopride to analyze actions of 5-hydroxytryptamine on enteric neurons.
    Wade PR; Mawe GM; Branchek TA; Gershon MD
    Am J Physiol; 1991 Jan; 260(1 Pt 1):G80-90. PubMed ID: 1987811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and treatment of the gastric symptoms of radiation sickness.
    Dubois A; Fiala N; Boward CA; Bogo V
    Radiat Res; 1988 Sep; 115(3):595-604. PubMed ID: 3174940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renzapride in IBS: is efficacy in the eye of the beholder?
    Ford AC
    Aliment Pharmacol Ther; 2010 Jul; 32(1):113-4; author reply 114-5. PubMed ID: 20597877
    [No Abstract]   [Full Text] [Related]  

  • 18. Emesis and defecations induced by the 5-hydroxytryptamine (5-HT3) receptor antagonist zacopride in the ferret.
    King GL
    J Pharmacol Exp Ther; 1990 Jun; 253(3):1034-41. PubMed ID: 2162943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [(125I)iodo-zacopride: new ligand for the study by autoradiography of central 5-HT3 receptors].
    Koscielniak T; Ponchant M; Laporte AM; Guminski Y; Verge D; Hamon M; Gozlan H
    C R Acad Sci III; 1990; 311(6):231-7. PubMed ID: 2121314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zacopride, a 5-HT3 receptor antagonist, reduces voluntary ethanol consumption in rats.
    Knapp DJ; Pohorecky LA
    Pharmacol Biochem Behav; 1992 Apr; 41(4):847-50. PubMed ID: 1594653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.